Nuformix PLC Notice of AGM (7165H)

TIDMNFX

RNS Number : 7165H

Nuformix PLC

31 July 2023

Nuformix plc

("Nuformix" or the "Company" or the "Group")

Notice of Annual General Meeting ("AGM")

Nuformix plc (LSE: NFX), a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurp osing, announces that the 2023 Notice of AGM has today been posted to its shareholders:

A full pdf version of the Notice of AGM will shortly be available for download from the Investor Information section on the Company's website www.nuformix.com .

The AGM will be held on 24 August 2023 at 10.00 am at the offices of Shakespeare Martineau, 6(th) floor, 60 Gracechurch Street, London, EC3V 0HR.

Enquiries:

 
 Nuformix plc 
 Dr Dan Gooding, Executive Director         Via IFC Advisory 
 Stanford Capital Partners Limited 
 Tom Price / Patrick Claridge (Corporate 
  Finance)                                  +44 (0) 20 3650 3650 
 John Howes / Bob Pountney (Corporate 
  Broking)                                  +44 (0) 20 3650 3652 
 IFC Advisory Limited 
 Tim Metcalfe                               +44 (0) 20 3934 6630 
  Zach Cohen                                 nuformix@investor-focus.co.uk

About Nuformix

Nuformix is a pharmaceutical development company targeting unmet medical needs in fibrosis and oncology via drug repurposing. The Company aims to use its expertise in discovering, developing and patenting novel drug forms, with improved physical properties, to develop new products in new indications that are, importantly, differentiated from the original (by way of dosage, delivery route or presentation), thus creating new and attractive commercial opportunities. Nuformix has a pipeline of pre-clinical assets with potential for significant value and early licensing opportunities.

For more information, please visit www.nuformix.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NOADFLBXXDLLBBD

(END) Dow Jones Newswires

July 31, 2023 09:00 ET (13:00 GMT)

Nuformix (LSE:NFX)
Historical Stock Chart
From Nov 2024 to Dec 2024